CLVS News and Press, Clovis Oncology Inc. From 10/03/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Faizal Ramli/Shutterstock.com Xperi (NASDAQ: XPER ) stock is falling on Friday after the company completed a spinoff of itself from its IP licensing business. That spinoff has Xperi separating itself...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: A.PAES / Shutterstock.com Petrobras (NYSE: PBR ) stock is getting a boost on Monday thanks to a couple of positive bits of news for the Brazilian oil company. First up is talk that OPEC Plus will like...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a still-fresh press release, Clovis Oncology (NASDAQ: CLVS ) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint . Moreover, Clovis plans to submit a suppl...

Clovis Oncology ( NASDAQ: CLVS ) said its medicine Rubraca helped extend the lives of patients with a type of prostate cancer without their disease getting worse, achieving the main goal of a phase 3 trial. The study, dubbed TRITON3, enrolled patients with...

TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM achieved the primary endpoint of improved radiographic progression-free...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Koshiro K / Shutterstock Xpeng (NYSE: XPEV ) stock is on the move Wednesday after the electric vehicle (EV) company revealed its new flagship G9 SUV. Let’s go over all of the details investors i...

Clovis Oncology ( NASDAQ: CLVS ) said on Wednesday it had signed a clinical supply agreement that would provide it with Isotopia’s lutetium-177 n.c.a. for use in the development of FAP-2286, fibroblast activation protein, that targets therapeutic candidate. ( ...

Isotopia to supply its medical radioisotope, lutetium-177, for the clinical development of Clovis Oncology’s targeted radionuclide therapy candidate FAP-2286 Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Clovis Oncology (NASDAQ: CLVS ) stock are in focus after the company received positive results from its early Phase 3 clinical trial. However, shares of CLVS stock are down about 5% today after August&#x...

Clovis Oncology ( NASDAQ: CLVS ) said it submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for approval of Rubraca (rucaparib) as a first-line maintenance therapy for women with advanced ovarian cancer reg...